Lartruvo (olaratumab) / Eli Lilly  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lartruvo (olaratumab) / Eli Lilly
KEYNOTE-505, NCT03126591: A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed
1a/1b
38
Europe, US
Olaratumab, LY3012207, Pembrolizumab, MK3475
Eli Lilly and Company, Merck Sharp & Dohme LLC
Soft Tissue Sarcoma
05/21
02/23
OLATRASTS, NCT03985722: Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients

Active, not recruiting
1
28
Europe
Olaratumab and Trabectedin, Lartruvo and Yondelis
Grupo Espanol de Investigacion en Sarcomas
Sarcoma, Soft Tissue
02/21
05/24
ZOLAR, NCT06537596: 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma

Not yet recruiting
1
50
RoW
89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
Telix Pharmaceuticals (Innovations) Pty Ltd
Soft Tissue Sarcoma
12/25
06/26

Download Options